Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19

Hui-min SUN; Feng XU; Ling ZHANG; Cong WEI; Jie-yong CHEN; Qiu-xin WANG; Zhen-hua JIA

doi:10.13422/j.cnki.syfjx.20201438

您当前的位置：

首页 >

文章列表页 >

Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19

Topic on Epidemic Resistance (Ⅳ) | 更新时间：2020-09-09

- Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 14, Pages: 29-34(2020)
- 作者机构：
  
  1. 唐山市中医医院，唐山 063000
  2. 沧州市人民医院，沧州 061000
  3. 河北省胸科医院，石家庄 050041
  4. 络病研究与创新中药国家重点实验室，石家庄 050035
  5. 河北以岭医药研究院，石家庄 050035
  6. 衡水市第三人民医院，衡水 053000
  7. 唐山市传染病医院，唐山 063000
  8. 河北以岭医院，石家庄 050091
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20201438
  CLC： R22;R24;R373.1
- Published Online：17 April 2020，
  
  Published：20 July 2020
- 稿件说明：
移动端阅览
孙惠敏,徐锋,张玲等.连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察[J].中国实验方剂学杂志,2020,26(14):29-34.

SUN Hui-min,XU Feng,ZHANG Ling,et al.Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(14):29-34.
孙惠敏,徐锋,张玲等.连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察[J].中国实验方剂学杂志,2020,26(14):29-34. DOI： 10.13422/j.cnki.syfjx.20201438.

SUN Hui-min,XU Feng,ZHANG Ling,et al.Study on Clinical Efficacy of Lianhua Qingke Granule in Treatment of Mild and Ordinary COVID-19[J].Chinese Journal of Experimental Traditional Medical Formulae,2020,26(14):29-34. DOI： 10.13422/j.cnki.syfjx.20201438.

摘要

目的

评价中药连花清咳治疗新型冠状病毒肺炎的临床有效性和安全性。

方法

采用随机对照临床研究方法，纳入依据《新型冠状病毒感染的肺炎诊疗方案（试行第六版）》诊断为新型冠状病毒肺炎且存在咳嗽症状的18岁以上患者。采用随机数字表法分为对照组和观察组，分别给予常规治疗或加服连花清咳颗粒（1袋/次，3次/d）治疗14 d。主要评价指标为咳嗽症状消失率。

结果

57例受试者纳入本研究，其中对照组25例，观察组32例。观察组咳嗽症状消失率为90.6%（29/32），明显高于对照组的64.0%（16/25）（

0.05），观察组的咳嗽治疗起效时间明显早于对照组（

0.05），咳嗽症状持续时间明显短于对照组（

0.05）。观察组的咳痰症状消失率为94.7%（18/19），明显高于对照组的57.1%（8/14）（

0.05），且观察组的咳痰治疗起效时间明显早于对照组（

0.05），咳痰症状持续时间明显短于对照组（

0.05）。观察组的CT好转率为96.9%（31/32），明显高于对照组的72.0%（18/25）（

0.05）。经过治疗后，两组受试者的氧合指数有不同程度升高，观察组的氧合指数升高率（52.7%）明显高于对照组（23.9%）（

0.05）。观察组发热、乏力、咽干、咽痛症状消失率与对照组比较，差异无统计学意义，但显示出在常规治疗基础上加用连花清咳有较好的改善趋势。

结论

在常规治疗基础上加用连花清咳可以显著改善新冠肺炎患者的咳嗽、咳痰症状，促进咳嗽、咳痰症状改善，缩短咳嗽、咳痰症状持续时间，减轻肺部病变，改善呼吸功能，对发热、乏力、咽干、咽痛症状也显示出良好改善趋势。

Abstract

Objective

To evaluate the clinical efficacy and safety of traditional Chinese medicine Lianhua Qingke granule （LH granule）in the treatment of coronavirus disease 2019（COVID-19）.

Method

A randomized controlled method was used in this clinical study. The subjects were confirmed COVID-19 patients over 18 years old with cough symptoms，and the diagnosis is based on

Diagnosis and Treatment Protocol for COVID-19

（

Trial Version 6

）. The subjects were randomized to usual treatment （control group） or in combination with LH granule （1 bag，thrice daily） for 14 days. The primary endpoint was the rate of cough recovery.

Result

57 subjects were included in this study， including 25 in the control group and 32 in the observation group. The recovery rate of cough in observation group was 90.6%（29/32）， which was significantly higher than 64.0%（16/25）in the control group （

0.05）. The effective time of cough treatment was significantly earlier than that of the control group （

0.05）， the median time to cough recovery was markedly shorter in treatment group （

0.05）. The recovery rate of expectoration in observation group was 94.7% （18/19）， which was significantly higher than 57.1%（8/14）in the control group （

0.05）. The effective time of expectoration treatment was significantly earlier than that of the control group （

0.05）， and the median time to expectoration recovery was markedly shorter in treatment group （

0.05）. The improvement rate of CT in the observation group was 96.9% （31/32）， which was significantly higher than 72% （18/25） in the control group （

0.05）. After treatment， the oxygenation index of the two groups increased in varying degrees， and the increase rate of the observation group was significantly higher than that of the control group （

0.05）. There was no significant difference in the recovery rate of fever， fatigue， dry pharynx and sore throat between the observation group and the control group， and it showed that LH had a better improvement trend on the basis of usual treatment.

Conclusion

On the basis of routine treatment，LH can significantly improve the symptoms of cough and expectoration of COVID-19 patients， shorten the duration of cough and expectoration symptoms， reduce lung pathological damage， improve respiratory function， and improve the symptoms of fever， fatigue， dry pharynx and sore throat.

关键词

Keywords

references

国家卫生健康委员会，国家中医药管理局 . 《新型冠状病毒肺炎诊疗方案（试行第七版）》 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml ， 2020-03-04 / 2020-03-28 .

World Healthy Organization . Coronavirus disease 2019（COVID-19） situation report-65 [EB/OL]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200325-sitrep-65-covid-19.pdf?sfvrsn=2b74edd8_2 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200325-sitrep-65-covid-19.pdf?sfvrsn=2b74edd8_2 ， 2020-03-25 / 2020-03-28 .

World Healthy Organization . WHO Director-General's opening remarks at the media briefing on COVID- 19 - 11 March 2020 [EB/OL]. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 ， 2020-03-20 / 2020-03-28 .

LI X ， WANG L W ， YAN S N ， et al . Clinical characteristics of 25 death cases with COVID-19:a retrospective review of medical records in a single medical center，Wuhan，China [J]. Int J Infect Dis ， 2020 ， doi： 10.1016/j.ijid.2020.03.053 http://dx.doi.org/10.1016/j.ijid.2020.03.053 .

杨立波，高学东，刘贵颖，等 . 连花急支片治疗急性气管-支气管炎的随机双盲、安慰剂平行对照、多中心Ⅲ期临床研究 [J]. 中药药理与临床， 2016 ， 32 （ 2 ）: 193 - 196 .

谷春华，任君霞，杨立波，等 . 连花急支片治疗急性气管-支气管炎痰热壅肺证随机双盲多中心临床试验 [J]. 中国中医药信息杂志， 2015 ， 22 （ 9 ）: 18 - 21 .

杨立波，王保群 . 连花急支片与抗生素治疗急性气管-支气管炎的随机对照临床研究 [J]. 中国医药导报， 2015 ， 12 （ 19 ）: 128 - 131 .

国家卫生健康委员会，国家中医药管理局 . 关于印发新型冠状病毒感染的肺炎诊疗方案（试行第六版）的通知 [EB/OL]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml ， 2020-02-18 / 2020-03-06 .

吕睿冰，王文菊，李欣 . 中药连花清瘟治疗新型冠状病毒肺炎疑似病例63例临床观察 [J]. 中医杂志， 2020 , doi: 11.2166R.20200215.1633.004 http://dx.doi.org/11.2166R.20200215.1633.004 .

程德忠，李毅 . 连花清瘟颗粒治疗54例新型冠状病毒肺炎患者临床分析及典型病例报道 [J]. 世界中医药， 2020 ， 15 （ 2 ）: 150 - 154 .

段璨，夏文广，郑婵娟，等 . 金花清感颗粒治疗新型冠状病毒感染肺炎的临床观察 [J]. 中医杂志， 2020 ， doi： 11.2166.R.20200323.0853.002 http://dx.doi.org/11.2166.R.20200323.0853.002 .

贾振华 . 络病理论指导新型冠状病毒肺炎证治探讨 [J]. 中国实验方剂学杂志， 2019 ， doi： 10.13422/j.cnki.syfjx.20201146 http://dx.doi.org/10.13422/j.cnki.syfjx.20201146 .

郑茂，张玉凤，张晓芳，等 . 呼吸指数及氧合指数在儿童ARDS中的临床意义 [J]. 中国妇幼健康研究， 2019 ， 30 （ 9 ）: 1144 - 1147 .

周霞，冯娜娜，李静，等 . 连花急支片在慢性支气管炎大鼠中的药效学研究 [J]. 复旦大学学报， 2017 ， 44 （ 1 ）: 21 - 26 .

谷春华，王宏涛，朱慧明，等 . 连花急支片治疗急性支气管炎药效学研究 [J]. 亚太传统医药， 2015 ， 11 （ 9 ）: 9 - 11 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Chinese Patent Medicines in 2020 Edition of Chinese Pharmacopoeia (Part Ⅰ) for Cough of Children

Syndrome Distribution of 9 323 Cough Cases in Ancient Chinese Medical Books Based on Latent Structure Model and Logistic Regression Analysis

Prescriptions and Syndromes of 9 323 Cough Cases in Ancient Chinese Medical Books Based on Rules of Latent Structure Differentiation

Retrospective Clinical Analysis on Treatment of Coronavirus Disease 2019 with Traditional Chinese Medicine Lianhua Qingwen

Clinical Efficiency of Modified Erchentang on Children Bronchiolitis

Related Author

Jian-xun LIU

Zi-xin LIU

Shu-juan XU

Lei LI

Fei-fan JIA

Hao GUO

Wen-li CHEN

Kun LIU

Related Institution

Eye Hospital， China Academy of Chinese Medical Sciences

Xiyuan Hospital， China Academy of Chinese Medical Sciences

Binzhou Medical University

Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immuoregulation，Nanyang Institute of Technology

Respiratory Disease Prevention and Control of Provincial Department of Traditional Chinese Medicine to Build Collaborative Innovation Center，Henan Key Laboratory of Chinese Medicine for Respiratory Disease，Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰